Literature DB >> 2547657

Mu type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to G-protein-mediated inhibition of adenylyl cyclase.

J P Fedynyshyn1, N M Lee.   

Abstract

The periaqueductal gray (PAG) region of the midbrain has been implicated in both stimulation-produced and opioid-induced analgesia. High-affinity mu-selective opioid-binding sites associated with mu type opioid receptors have been detected in rat PAG-enriched P2 membranes, and these receptors have been shown to be coupled to guanine nucleotide-binding proteins (G-proteins). In the present study the potential G-protein-mediated coupling of mu type opioid receptors to the inhibition of adenylyl cyclase was examined utilizing in vitro adenylyl cyclase assays. In the presence of Na+, opioid agonists inhibited adenylyl cyclase in a mu selective, naloxone reversible, dose dependent, and pertussis toxin sensitive manner. Overall the data suggests that mu type opioid receptors in the rat PAG are coupled to G-protein-mediated inhibition of adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547657     DOI: 10.1016/0014-5793(89)80921-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  GPR171 activation regulates morphine tolerance but not withdrawal in a test-dependent manner in mice.

Authors:  Leela Afrose; Max V McDermott; Ashif I Bhuiyan; Sanjai K Pathak; Erin N Bobeck
Journal:  Behav Pharmacol       Date:  2022-08-05       Impact factor: 2.277

Review 2.  An emerging new paradigm in opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray.

Authors:  Handong Ouyang; Shue Liu; Weian Zeng; Roy C Levitt; Keith A Candiotti; Shuanglin Hao
Journal:  ScientificWorldJournal       Date:  2012-08-02

3.  Opioid and GABAB receptors differentially couple to an adenylyl cyclase/protein kinase A downstream effector after chronic morphine treatment.

Authors:  Elena E Bagley
Journal:  Front Pharmacol       Date:  2014-06-24       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.